Darling Ingredients Inc.

answer period and instructions to ask a question will be given at that time. Today's call is being recorded. I would now like to turn the call over to Ms. Sue Ann Guthrie, Senior Vice President of Investor Relations. Please go ahead.

Thank you for joining the Darling Ingredients second quarter 2025 earnings call. Here with me today are Mr. Randall C. Stewie, Chairman and Chief Executive Officer, Mr. Bob Day, Chief Financial Officer, and Mr. Matt Jansen, Chief Operating Officer, North America. Our second quarter 2025 earnings news release and slide presentation are available on the investor page of our corporate website and will be joined by a transcript of this call once it is available. During this call, we will be making forward-looking statements, which are predictions, projections, or other statements about future events. These statements are based on current expectations and assumptions that are subject to risks and uncertainties. Actual results can materially differ because of factors discussed in today's press release and the comments made during this conference call and in the risk factors section of our Form 10-K, 10-Q, and other reported filings with the Securities and Exchange Commission. We do not undertake any duty to update any forward-looking statements. Now, I will hand the call off to Randy.

Good morning. Thanks, Sue Ann, and thanks everybody for joining us for our second quarter 2025 earnings call. This quarter, we saw early signs of momentum building across our businesses, even as we continue to navigate a complex renewable fuel environment. We delivered positive earnings, maintained strict capital discipline, and enhanced our financial flexibility through a successful refinancing. We locked in our borrowing costs for the next five plus years, and we positioned ourselves to invest confidently in long-term growth. We also advanced our strategic agenda with the announcement of our intention to form NextIDA, our new joint venture focused in the health and wellness space. This move aligns with our strategy to diversify and grow in high margin, high growth, like health and wellness. Combined adjusted EBITDA for the quarter came in at $249.5 million. While the regulatory environment has been a headwind in recent quarters, We are now seeing signs of clarity and constructive market changes, particularly in our feed segment, setting us up for a stronger performance in the second half of 2025 and into 2026. DGD continues to face near-term pressure, but we remain confident in its long-term value as policy support begins to take hold. Across the board, we're focused on execution and believe the fundamentals are now moving in the right direction. Now turning to the feed ingredient segment, global rendering volumes are steady and in line with our expectations. We saw margin expansion both quarter over quarter and year over year, reflecting focused execution, operational efficiency, and improved premium ingredient pricing. Rising fat prices, supported by recent public policy that favors domestic sources, are creating a favorable pricing environment, which we expect to continue and expand. As a result, a larger portion of our domestic fat portfolio is now headed to DGD. Tariff volatility and increased domestic oilseed crush has put pressure on protein prices, especially on our sales into Asia. However, fat prices are outweighing the higher protein supply and softer prices. Now, turning to our food segment. As I mentioned, we signed a non-binding term sheet with the center load to form next item. We are concluding due diligence and expect to sign a definitive agreement in this quarter. We believe this platform already is a meaningful contributor to earnings, has the potential to grow at an accelerated rate as we increase our presence in the health and wellness and nutrition market. Global demand for collagen and gelatin continues to strengthen, driven by health, wellness, and functional nutritional needs. We're advancing scientific validation for next tie to GC, our glucose control product. These studies are near complete and early results are showing strong potential. And we're beginning to see repeat orders for this product as well. In our fuel segment, the renewables environment remains difficult. The overhang on small refinery exemptions and delayed 2024 RIN compliance enforcement is preventing mandates from reflecting real demand and continuing to put pressure on renewable fuel margins. However, DGD remains a leader, consistently delivering best-in-class performance. SAF volumes continue to demonstrate flexibility and resilience and are helping us to balance the difficult market dynamics. We are seeing the feedstock supply chain rebalance itself due to tariffs and regulatory and tax changes, all benefiting Darling's core business. In addition, changes implemented by CARB to increase mandated greenhouse gas reductions in California as of July 1, and we expect LCFS premiums will strengthen and support margin recovery over time. Meanwhile, the proposed RVO framework represents a major tailwind for the renewables market and RINs, as long as mandated volumes, net of SREs are anywhere close to what has been proposed, it will reinforce long-term demand and support a healthy margin environment. DGD 1, however, will remain offline until margins show some meaningful improvement. Meanwhile, DGD 3 is scheduled for a turnaround starting here in third quarter. The timing aligns well with our outlook, positioning us for full utilization as policy rules are clarified later in 2025 and enabling DGD to run full in 2026 when we anticipate a significantly stronger margin environment. We believe that the groundwork we're laying now through operational discipline and strategic timing positions us well when the margin environment improves. Now with that, I'd like to hand the call over to Bob to take us through the financials, and I'll come back and give you my thoughts on the balance of 2025. Bob?

Thank you, Randy. Good morning, everyone. For second quarter of 2025, Darling's combined adjusted EBITDA was $249.5 million versus $273.6 million in the second quarter of 2024. In adjusting for DGD, second quarter 2025 EBITDA was approximately 207 million versus approximately 197 million in the second quarter of 2024. Year-to-date combined adjusted EBITDA totaled 445.3 million as compared to 553.7 million for the same period of 2024. Total net sales in the second quarter of 2025 were 1.48 billion versus 1.46 billion in the second quarter of 2024. while raw material volume was almost the same at 3.74 million metric tons and 3.76 million metric tons. Year-to-date volumes for 2025 were 7.53 million metric tons compared to 7.56 million metric tons for the same period, 2024. Gross margins improved to 23.3% for the second quarter of 2025 compared to 22.5% in the second quarter of 2024. We also saw a nice gross margin improvement year to date at 23.0% for the first six months of 25 compared to 21.9% for the first half of 2024. Looking at the feed segment, total net sales increased and EBITDA improved on relatively unchanged volumes. Total sales for the second quarter of 2025 were $936.5 million versus $934.1 million in the second quarter of 2024. For the six months TAB, Mark McIntyre, 2025 total sales were 1.83 billion compared to 1.82 billion for the same time in 2024 feed raw material volumes were approximately 3.1 million metric times for both quarters and material unchanged year over year at roughly 6.2 million metric times. TAB, Mark McIntyre, For second quarter 2025 gross margins improve nicely to 22.9% versus 21.0% in the second quarter of 2024. Meanwhile, lower protein values created a slight headwind that will alleviate as we continue to find better markets for premium protein products. And while fat prices moved considerably higher during the second quarter, the lag between raw material procurement and finished fat sales resulted in lower margins than we expect to see as prices flatten. All things considered, we are pleased with the improvement in gross margins for the quarter. And as Randy said, the outlook is very positive. Tom Frantz, Here today gross margins were also better at 21.6% compared to 20.9% in the first six months of 2024. Tom Frantz, Moving to the food segment, the margin environment continued to show healthy signs, as we were able to. Tom Frantz, maintain gross margins per unit sold, while increasing sales volumes total sales for the second quarter of 2025 or 386.1 million higher than second quarter 2024 at 378.8 million. Second quarter 2025 gross margins for the food segment were unchanged from quarter two of 2024 at 26.9%. Year-to-date gross margins for 2025 were 28.1% versus 25.3% from the same time a year ago. Raw material volumes increased to 323,900 metric tons versus 304,700 metric tons. Year-to-date raw material volumes for the food segment were 653 1,400 metric tons compared to 604,400 metric tons, reflecting an increase in global demand. EBITDA for the second quarter of 2025 was slightly down at 69.9 million versus 73.2 million in the second quarter of 2024, while year-to-date 2025 EBITDA was 140.9 million versus 134.9 million from the same period a year ago. Looking at the fuel segment, as Randy mentioned, the renewable fuel environment continued to be challenging. Darling's share of DGD EBITDA was approximately 42.6 million for the second quarter of 2025 versus approximately 76.6 million of EBITDA for the second quarter of 2024. Year-to-date 2025, Darling's share of DGD EBITDA was 48.7 million versus 191.7 million for the first six months of 2024. In the second quarter of 2025, the impact to Darling for LIFO was negative 31.1 million, and it included a lower of cost or market or LCM benefit of 55.6 million. Year to date, LIFO for Darling's half of DGD was negative 59.5 million, while LCM generated a positive 101.1 million. Overall fuel segment sales for the second quarter of 2025, which does not include DGD, were 158.8 million versus 142.3 million in the second quarter of 2024. Year-to-date sales in 2025 were 293.9 million versus 281.5 million in 2024. Raw material volumes in the second quarter of 2025 were 337,600 metric tons versus 362,000 metric tons in the second quarter of 2024. Year-to-date raw material volumes in 2025 were 711,700 metric tons versus 718,900 metric tons for the same period in 2024. Combined adjusted EBITDA for the full fuel segment was $61.3 million in the second quarter of 2025 versus $96.8 million in the second quarter of 2024. In year-to-date 2025 fuel segment combined, adjusted EBITDA was $85.5 million compared $29.9 million in 2024. During the second quarter, we accomplished several important objectives related to our credit and balance sheet, providing the company with a significant amount of flexibility and stability for the next five to seven years. First, we've refinanced and upsized our Euro bond from 515 million Euro to 750 million for seven years at a fixed rate of 4.5%. Second, we paid off our revolving credit facility and the four remaining term loan aid facilities replacing them with $2.9 billion in credit facilities through two senior secure debt agreements. First, a five-year $2 billion revolver, and second, a six-year $900 million farm credit term loan A. While the Euro bond at 4.5% replaced the previous Euro bond at 3.58%, the upsizing of the bond allowed us to maintain an average cost of borrowing materially unchanged while ensuring a stable financial position for many years. The company's total debt, net of cash, and other items as of June 28, 2025 was $3.89 billion versus $3.97 billion on December 28, 2024, helping lower the preliminary leverage ratio to 3.34 times at the end of quarter two 2025 from 3.93 times at the year end 2024. In addition, we ended the second quarter of 2025 with approximately $1.27 billion available on our revolving credit facility. Capital expenditures totaled $71 million in the second quarter of 2025 and $134 million for the six months of 2025. The company recorded an income tax expense of $4.1 million for the three months ended June 28, 2025, yielding an effective tax rate of 22.2%, which is slightly higher than the federal statutory rate of 21%, due primarily to certain losses that provided no tax benefit offset by the producer's tax credit. The effective tax rate, excluding the impact of the producer's tax credit and discrete items, was 3.4% for the three months ended June 28, 2025. The company also paid $22.8 million of income taxes in the second quarter and $32 million year-to-date. For 2025, we expect the effective tax rate to be around 15% and cash taxes of approximately $40 million for the remainder of the year for a projected total of around $72 million. Overall, the company's net income was $12.7 million for the second quarter of 2025, or $0.08 per diluted share, compared to net income of $78.9 million, or $0.49 per diluted share, for the second quarter of 2024. In year-to-date 2025, Darling had a net loss of $13.5 million, or negative $0.09 per diluted share. Now I will turn the call back over to Randy.

Thanks, Bob. Now, as we look ahead, we remain confident in the strength of our business, particularly our core ingredients platform, which continues to benefit from a favorable public policy outlook. We expect sequential improvement across the board with rising fat prices supporting our feed segment. While premium proteins remain a modest headwind, we're seeing signs of stabilization. At DGD, although the current environment remains challenging and volumes will be lower in the third quarter due to a planned turnaround, We believe this sets us up well for full utilization in 2026. While the timing of RIN recoveries remains uncertain due to ongoing small refinery exemption issues, we anticipate a more constructive market environment ahead. Based on what we see today, we expect full year combined adjusted EBITDA in the range of $1.05 billion to $1.1 billion. With that, now let's go ahead and open it up to questions.

Of course. We will now begin the question and answer session. We ask that all participants only ask one question and one follow up. If you'd like to ask a question, please press star followed by one on your telephone keypad. If for any reason you'd like to remove that question, please press star followed by two. Again, to ask a question, press star one. As a reminder, if you are using a speakerphone, please remember to pick up your handset before asking a question. Our first question comes from the line of Manav Gupta with UBS. Your line is now open.

Good morning guys. My first question is when we look at the revised RVO much higher coupled with 50% friends for foreign feedstock and no PTC for imported RD, this makes dollar real winner. Can you talk about some of the policy benefits which want more domestic renewable made for more domestic feedstock, and how that really benefits Darling Ingredients?

Hi, Manal. Good morning. This is Matt. I'll start off and then maybe ask Randy or Bob to kick in. But you're absolutely right in terms of we see this going forward as more of an evolving into a domestic-oriented market, more so than what we have seen in the past. we expect a drop in imported raw material. And as a result, we're seeing the benefit of that in our U.S. fat pricing. And through the quarter, fat prices were moved up significantly. And we see that continued trend and fat prices maintaining being well supported. So our focus right now in the U.S. is on reliability and making sure our our processing plants on the raw material side can run as planned and as expected, so we can continue to maximize the production of the U.S. fat to supply the RD market.

This is Bob. So I agree with Matt. It is very supportive to U.S. or North American fat values. You know, that's great for Darling. It doesn't really hurt us so much outside of the U.S., because of the dynamics of the regional markets there. So overall, that's good for the feed segment. It's also, if the RVO and the stated mandate holds as a mandate, net of SREs, which we're all kind of waiting to see, but if it does hold as a mandate, then it's very positive in our view for renewable diesel margins just based on the supply and demand and capacity availability to produce renewable diesel and biodiesel in the United States relative to that demand number. You know, we see those things as positive. The 50% RIN, an interesting policy dynamic if we see that whole, and it would support those things. It would eliminate access to foreign feedstocks, which is some flexibility we like, but, you know, the other positive impacts outweigh the negative impact of that.

Perfect. My quick follow-up here is amended LCFS has gone into effect. Carbon prices are already moving up. I think they're close to $55. Prices were higher before OAL stepped in and kind of blocked it. So I'm just trying to understand, do you guys still expect that we could get to like $70 a ton by year end? And if everything is right, then maybe even $80 in 2026. So your outlook for LCFS prices and again, how it benefits darling ingredients. Thank you.

So I think the first thing I'd say is what we view as very positive is now that with the increased greenhouse gas obligation or elimination of greenhouse gas obligation in California, we're starting to see the bank finally coming down. And that's a very positive sign. Based on where we are today and what we see playing out, this bank will continue to decrease How that results exactly in price per ton of LCF credits, it's very hard to estimate that. That's going to depend on obligated parties in California, the sense of urgency they feel that they need as far as procuring those credits. But we agree that it's moving in a positive direction and likely to head higher.

Thank you for your question. Our next question comes from the line of Heather Jones with Heather Jones Research. Your line is now open.

Good morning. Thanks for the question. My first one is on UCO. So, in your slide deck, you talk about, I think it was a roughly 13 million year-on-year hit from lower UCO pricing, whereas, you know, spot pricing for the last two to three quarters was suggested would have been higher. So, just wondering if you could explain to us what happened in the quarter and maybe the year-to-year comparison. that would cause that and when we should expect to see the current pricing we're seeing come through.

Yeah, thanks, Heather. I'm trying to get to that slide on the deck. I think the, let me just address the last part of your question first. You know, the dynamics of that market are, it's very fluid. And so, as we are pricing with suppliers, The timing at which we're pricing relative to the indication we use, or let's say the timing at which we sell product relative to the timing at which we price for suppliers, those can be different. And in a rising market like we've had in the last quarter, that can work against us. You know, what we expect is as prices flatten at a higher level where we are today, then uh then then the margin is is higher because of our percentage that we keep of the total price but i think during the quarter what we saw was we're selling out in front um fixing prices as the index continues to go higher when we set the price that we're paying it's it's higher than what it was at the time we sold and so that's that's the biggest impact that we had on that yeah that that's well said bob i mean really in what you're looking at heather is in a rising

raw material procurement market which we're in with forward sales it's always the lag effect as things go accelerate here i think what's most important today is uh as we lay the uh the outlook is q3 fat prices really you got to look at yellow grease and yuko as both of those go to diamond green diesel a bigger share of our our mix now in north america is going to diamond green diesel And the prices are up anywhere from $0.10 to $0.14 a pound over Q2. In Q2, you really only saw versus Q1 about a $60 a ton or a $0.03 a pound price rise between the Yuko and the yellow grease as it flowed through the P&L. And that's just a typical lag factor.

Okay, thank you. My second question is, with the exception of that change in fair value of contingent consideration that was noted in the price release in the feed segment, just wanting to know, is there anything unusual in this quarter's results, whether it be inventory adjustment, insurance recoveries, or whatever, that would affect the comparability for Q3 and later quarters to this quarter? I'm just like wondering if this is like a, I guess, a clean quarter for us to build on going forward.

Yeah, thanks, Heather. I think the price lag in fats, it affected us across all the fats in the segment. So I would say it wasn't, to use your term, a clean quarter from that standpoint. I think as we get into the third quarter here, we are sort of operating in a higher level environment. We're not seeing a situation so far where we're pricing our suppliers at a higher value than what we had to sell. And so this will probably be more reflective of that. But that was a pretty significant impact in the second quarter. Other than that, we did have some deferred profit losses that will come back in the third quarter from related party sales.

The contingent valuation, Heather, is related to the Brazilian acquisition that had an earn out attached to it that completed or will complete here at the end of july and that's just an adjustment and that's representative of that business operating now really well thank you for your questions our next question comes from the line of sushant alani with jeffries your line is now open

Hi, team. Good morning. Thanks for taking my questions. Maybe the first one, could you talk to the opportunities for darling offer DGD other outside of California, margins in Canada, Oregon, you also seem to be forming up some so we're going to share how much of you know, RD you are exporting outside of California shipping outside of California versus within California and how that's going to evolve.

Hi, this is Matt. I would say that California is a big market in the R&D space, but it's by far not the only market. And we sell a lot of our product on an ongoing basis in various other states that are here in the U.S., but we also export quite a bit and predominantly to the U.K. and Europe. And so as these tariffs and all the different Moving parts, let's say, that have come about continue to play out. That mix may shift from one to the other, but we continue to be a significant exporter of RD to Europe and the UK.

Yeah, and I think the other thing I would add to what Matt's saying there that's spot on is I think this morning you saw the Nest Day release. And the positive takeaway for me there is there's always been some consternation that demand is diminishing out there, and it's absolutely not. It's growing for RD around the world, and it's growing for SAF, and margins are improving.

Got it. Thank you. And then just my next one, and I think you guys have also touched on it some, on just the SREs. What are your expectations? for what the EPA could do with these SREs? I mean, just based on the conversation that you guys have been having with folks in the industry.

That's the million-dollar question. This is Matt again. That's the million-dollar question. The SREs we expect will come sometime in the next, let's say, 60 days. Don't know exactly when that announcement will become public. But frankly, we don't have a clear view on what that number is going to be. There's lots of chatter out there. But frankly, as far as I'm concerned, no one really knows what that number is going to be. So we're anxiously awaiting that. And it's not only the number, but also how they get treated, whether they are, let's say, reallocated back or not. TAB, Mark McIntyre, And so that's still to come, and like I mentioned, we think that's imminent here in the next few weeks, but we're we're anxiously awaiting that.

TAB, Mark McIntyre, yeah and I would add to what matt saying there, I mean there at the end of the day we've modeled two or three different scenarios here and really the rbo is big enough to accept and and adapt to whatever whatever avenue they take and so. T. John McCune, M.D.: : In the end of the day, it is a bit of a hangover out there, and I think that that's why we. T. John McCune, M.D.: : In a sense, just to clarify for everybody on the call why we lower guidance it's not because of the core ingredient business core ingredient business. T. John McCune, M.D.: : is as exciting as it's ever been it's just we don't know the timing of when the marketplace is going to react, meaning rents and lcfs to whatever the SRE adjustment it's going to be.

Thank you for your questions. Our next question comes from the line of Derek Whitfield with Texas Capital. Your line is now open.

Good morning, all, and thanks for taking my questions. Beginning on 45Z, the policy as approved places a cap on SAF at the $1 per gallon level. As you guys think about this, how does it impact your view on margins relative to RD given the state of the voluntary markets and the likely environment where we'll see less SAF supply?

Yeah, thanks, Derek. This is Bob. So ultimately, when DGD is looking at selling SAF, they add all components to inputs and sales price when they negotiate the price that they're selling and ultimately the margin that they're shooting for. um today you know it's made up of many different things the the support we we get from 45z today uh you know starts at 1.75 max it lands somewhere you know a dollar or in that range just with the change probably around 35 40 cents less would come from the ptc which then means if we're still shooting for the same margin we're going to have to get it in the premium that SAF sells at relative to renewable diesel. And, you know, we'll just see how that all plays out. Ultimately, SAF, really the price of SAF and the margins for SAF should be determined based on the supply and demand for SAF. And so we're not really uncomfortable with the change so much. We just, you know, are more focused on the overall supply and demand for SAF and getting fair value for the product and the margin.

And I would just add that one flexibility that we have, and we're not there yet, but we do have the flexibility to choose between whether we produce RD or SAF in our line. And so right now we're running SAF as much as we can, and we expect that to continue. But we do have that additional flexibility.

Great. Then with respect to food and your plans to advance the next slide at JV this quarter, Bob Yates, It appears your conversations are progressing better than expected, I guess, could you offer some color on the degree of synergy and growth acceleration you're seeing across the combined company.

Bob Yates, yeah I think you know so yeah thanks, this is Bob. Bob Yates, we're we're really excited about it and and and and we're encouraged by what we're seeing there's there's really we're limited in what we can say today, because we haven't signed definitive agreements and and. you know, the next step will be filing for antitrust. So we just want to be really cautious there. But I think, you know, what we see with the two different companies is very complementary geographic spread. So they're in some countries that we're not. That diversifies our portfolio. And that's especially helpful in, let's say, the current environment where, you know, the cost of trading between countries differs from country to country. And so that diversification is worth more than, what it might otherwise have been. And then there's also just kind of a practical capacity access that comes with that transaction that we're really excited about. They bring some very important extraction capacity and some hydrolyzed collagen capacity that's important in the fast-growing hydrolyzed collagen market. So when we put all those things together, there are some really exciting synergies There's always sort of the cost side of it. That's more straightforward. But the more exciting part is sort of the increased revenue opportunity.

Thank you for your questions. Our next question comes from the line of Ryan Todd with Piper Sandler. Your line is now open.

Thanks. Good morning. Maybe first, can you Randy Thompson, Can you maybe walk through what's assumed in your updated even that guidance for 2025 I think it implies roughly 25% improvement and quarterly even down the second half, compared with with what we saw in the second quarter, so. Randy Thompson, What do you see as the primary drivers improvement, can you maybe walk through what you've seen today that provide confidence in that number.

Randy Thompson, yeah Ryan, this is Randy and you know, obviously the. the number is a reflection of an improvement in the core ingredient business as related to flow through of higher fat prices, in a sense, catching up and leveling off relative to raw material prices moving up, the higher pay to the slaughterhouses. The challenge in Q2 was while the higher fat prices, even though the minimus were flowing through, we were playing catch up, but the higher premium proteins, as we refer to them. Let's call it low-ash chicken meal that goes to aquaculture. That was, you know, you had a tariff on one day, a tariff off one day, whether it was Vietnam or China. And just trying to adjust markets and customers was really a negative in there. We see that kind of steadying now. I'm not telling you a giant improvement there, but it feels like the disruption is less than it was in Q2 now. higher flow through of a fat prices. And then the, as my comments were earlier, I mean, it, you know, we're going to have DGD three offline here in August, it'll be on ready to run in September, I believe is the timing. So we'll have all plants with new catalysts ready to rock and roll, you know, September one, if you will, you know, if that RIN market starts to normalize and reflect what it's going to take from a variable profitability perspective, James Rattling Leafs, You the guidance that we threw out there could be extremely conservative or if it delays till January one the market doesn't react, and then I think we're really pretty much in the fairway here saying that will have you know minimal but. James Rattling Leafs, You know some type of contribution from dgb, especially the SAS side through the end of the year here.

James Forrest, Norcal PTAC, Good thanks, maybe that's a good segue to a follow up question on SAS I mean you're. James Forrest, Norcal PTAC, You know what seven eight eight plus months in the operations there can you maybe talk about. James Forrest, Norcal PTAC, What you've learned so far, how would you characterize demand is there anything that's been surprising on the staff front in terms of geographic mix of demand or pricing, etc, and then it's still a pretty young market. You know what, as you look at what kinks or challenges do you think still remain that may need to get ironed out over the coming months or years?

Yep. Hi. Hey, Matt. This is Ryan. This is Matt. I would say from what we've learned, you know, we started off running in last November, and operationally we have, I would tell you, as expected and done well. The thing that I would say surprising, for example, for the reduction in the PTC was something that wasn't necessarily in the cards when we planned this. But we've learned logistically, we've moved the product around, again, as expected. I would say over the last few months, maybe some of the conversations have gone a little bit quiet in terms of new business, just because of all of the associated noise related to the things that we all know about with the RBOs and the PTCs and the tariffs and all those things. It slowed things down a little bit, but we continue to see solid, let's say, demand. We're running well, making deliveries on contracts. We've got a good sales book on. So the returns are meeting or exceeding the expectations of the project, so we're very satisfied with it.

Thank you for your question. Our next question comes from a line of Matthew Blair with CPH. Your line is now open.

Hey, good morning, and thanks for taking my question. Maybe circling back to Nextida, could you talk a little bit more about what the scientific studies are showing here? We've run some of our own tests, and it appears to be quite impactful, quite an improvement. And then also, you know, I appreciate that you probably can't talk too much about Matthew Treskon- What the ebitda contribution, you know it's going to look like and what the potential there is, but, but I guess in terms of timing, do you think that next data would start to make a material impact in 2026 or is this the longer dated timeframe, thank you.

Bob White- yeah thanks Matthew this is Bob so the status of the trials are we were completing this summer, a second round of trials, with a much larger sample size. That is what the larger CPG companies have asked for in order for them to get comfortable marketing the product and really pushing it on the market. We're seeing the same thing that you talked about. So ultimately, what that product does is it stimulates GLP-1 secretion into the blood. That leads to controlling the post-meal sugar spike. know the symptoms around that are curbed appetite and um and just you know more more stable blood sugar those are those are really positive uh we've you know we're seeing the same thing with all the all the trials um the timeline on when we could see a big impact would be uh as we finish these trials in the summer we kind of go out and we um you know we we present all this to the large cpg companies and hopefully by the end of the year you know we're talking about much more significant volumes so in 2026 it can have a much bigger impact on EBITDA. It's really just going to depend on kind of what the, what this next round of trials shows and how compelling it is. But you know, like you pointed out in the test that you've done yourself, it is a really, it is really powerful and you know, we're seeing great results. Bob, you want to talk about the brain side real quick? Yeah. And I guess, you know, the interesting thing here is we, you know, we're rolling out a portfolio of products and, ultimately what our team is able to do is they identify what's the molecule that would cause the body to have a natural reaction that generates a helpful, targeted health benefit. And so by using a different mix of enzymes in the collagen, we can create a peptide profile that's unique and one that we can patent, and it causes that natural reaction in the human body. Um, so we've identified what that, what that combination looks like in order to help with memory retention, um, gut health, women's health, and, you know, all these products are in different stages of development, but, um, but it's a, it's a great process that our R and D team has been able to iron out. And so as you know, we're, we're excited about, uh, next day to GC, but, but we're really excited about, you know, what the portfolio products can mean for the company, uh, over the next several years.

and matt the uh you know i think your one of your question was um contribution you know clearly 26 we're going to get some acceleration here you know we were requested you know the this health and wellness sector in the world is is a very very large piece out there 60 or 80 billion dollars you don't need much for it to be significant into your portfolio here The clinicals are key on that. We're seeing, you know, reorders now of the GLP-1 or Nextida GC product now, which is really, really good news. You know, we're excited about it. If you look at the history, and I've always said, you know, in Sue Ann's deck is that the history of the food segment, which is really anchored by Rusillo slash Nextida here, And that business has been built off of the hydrolyzed collagen business out there that we developed. And this is really hydrolyzed collagen 2.0 now. And if we're half as successful in volume there, we can double the earnings in that segment. Now that's probably a three to five year window to get there. 26 should accelerate, 27 should be really meaningful.

Great. Great. Thanks for all the helpful commentary. And then I guess turning to the Brazil rendering outlook, you know, there's been a lot of chatter that the U.S. rendering outlook is excellent after the RBO and the 45Z tax changes. But could you talk about what you're expecting for Brazil? Do you think there'll be pressure from things like the RBO and tariffs? And, you know, do you expect to kind of reorient your your exported rendering volumes from Brazil to other markets. And then finally, could you remind us just the overall split between U.S. rendered volumes and Brazil rendered volumes for Darling? Is it, I don't know, like roughly 80-20? Thank you.

Yeah, good question, number one. You know, the Brazil for us in the rendering side has been a truly wonderful experience of You know, the challenge there has been taking a private company and making it public and making profits versus tax avoidance a priority here. Getting raw material procurement, margin management as part of the culture. I'd say we check the box now and we're doing very, very well there on that. You know, Brazil is an incredible place because right now as the U.S. cattle numbers are down, although cattle feedlots margins are way up. Brazil's numbers are moving sharply up. And so, you know, we've got a pile of raw material, as we call it down there. So life is pretty good. The reality of the arbitrage of fats out of there is, is Brazil has really developed a very strong biofuel market. And ultimately, you know, the percentage inclusion, I suspect, will rise again here in

it in 2026 i mean there there's no lack of tension here right now between the us and brazil and we acknowledge that but uh there's no problem with that being a domestic oriented business matt anything you want to add there i would just say uh the market's going to dictate where uh where these products flow and uh you know from a quality standpoint the brazilian quality uh for for rd is actually very good preferred but at the same time uh you know brazil like they can As Randy mentioned, their biodiesel program inside the U.S. can change, even with 1% change in that, which is expected, that can shift a whole lot more of the volume to stay at home there. So that will continue to play out, and the market's going to dictate where the flow goes on what gets exported. Historically, a fair bit of that has come to the U.S., but maybe that shifts towards Europe.

Thank you for your questions. Our next question is Hey, good morning.

Thanks for taking the questions. My first one, I was curious if you could comment on what you're seeing in terms of biofuels industry utilization rates and demand for feedstocks. It seems from the feedstock pricing like things are moving in the right direction, but you've talked about DGD1 still being offline. I'm sure there are others as well. So just curious to what extent you've actually seen production utilization rates pick up across the industry, and kind of related to that, where do RINs need to get to in order to encourage production to ramp more materially?

Yeah, thanks, Andrew. This is Bob. I think, you know, one thing we're seeing is a lower capacity utilization rate for biodiesel across the board, about half a capacity roughly, and that hasn't changed very much throughout the year. And we're seeing renewable diesel capacity utilization move slightly higher month to month through the year. I think our view on that is that's more about the market's view of where RINs are going than where they are today. And so if you think about it, if you're an obligated party and you can generate RINs and you believe that the RINs are going higher, you'll use this opportunity to make more RINs. While margins aren't great for renewable diesel, there's, you know, we've got enough information about future policy to suggest that margins and RIN values should be higher in the future. And so that is what we believe is encouraging the production of renewable diesel today to slightly go up month to month. And, you know, we'll probably continue to see that at least until we get, you know, final clarification on SREs and what the actual mandate is.

Okay.

And you'll hold. the RVO holds, we're going to need the capacity to return online to meet that obligation.

Yeah, Andrew, this is Randy. That was Matt. This is Randy. I think it's going to be interesting, at least from my chair, over the next 10 days to see some reporting of second quarter earnings for some of these RD plants that have been running. And that'll kind of tell you, are they running for fun or not?

Got it. Okay. That makes sense. And then my other question was just around your CapEx plans. You're tracking solidly below last year so far this year. It seems like from your commentary, you know, there's greater focus on capital discipline. So how should we be thinking about CapEx for your business for, you know, the remainder of this year, maybe even into next year? Is there any reason that that should accelerate or how should we be thinking about that? Thanks.

Yeah, I mean, look, I think we've been really clear about this, Andrew, that, you know, we're committed to paying down debt and getting our debt coverage ratio down below 3.0 by the end of the year. What you see in the form of our CapEx year to date is exactly that. We will see it go higher here in the summer. You know, winter projects are slowed down because of weather. But, you know, we're committed to keeping our CapEx at $400 million or lower for the year and And we'll see where we are and what our markets look like when we achieve our goals as far as debt coverage ratios and decide what to do at that point. But our goal is to continue to pay down debt.

Yeah. And this is Randy. I mean, the reality is I want to be clear about a couple of things. One, we're not capital starving any of the assets out there today by any means. We have delayed some growth projects here. Nothing that's material. But at the end of the day, you know, I think we're focused on getting below 3.0. You know, we're waiting for the sun to shine in 26 here.

Thank you for your question. Our next question comes from the line of Benjamin Callow with Clark. Your line is now open.

Hey, good morning, guys. Just following up on that last question. um you know in the past you guys have talked about uh maybe having a dividend or repurchasing shares uh just kind of thinking and then also saa sap too uh just thinking about the capital allocation as we move into 26 and you hit your debt targets and then i have a follow-up well yeah thanks ben this is bob um i think

staff to, you know, we need more much more clarity around the market before we move down that path. So you know, whether we get that or not in 2026, and whether we would move towards that in 2026 is entirely dependent on clarification of policies and near term margin environment that would be required to justify something like that. We're not we're not there today. So as we look at 2026, it's not currently you know, in the plans to move forward, those things can change. As we look at everything else, you know, we want to, I mean, I think that, first of all, if I look at the food segment, you know, we have a great plan there with the formation of Next Data and the joint venture that will allow us to continue to move, you know, to grow in that industry and space. And that's a non-cash transaction that provides access to that new capacity. So that's that's very convenient at a time like this where we can continue growing and it doesn't require capital. So that really leaves us with the feed segment. And, you know, there are opportunities for us to continue to grow our platform globally in the feed segment. You know, we're focused on getting to the right leverage ratios and getting our balance sheet in the right place before we move on any of those things. But, you know, we'll get to that point and then look at those opportunities. But right now, I think 2026 is likely to be maybe not as conservative as 25, but, but, you know, continue to be focused on, on paying down debt.

Okay, great. And just going back to the food segment, um, just in the interim between, uh, where we get to next side and the growth there, um, you know, last year there was some, uh, weakness in college and sales. It looks like it's, it bottomed out there. Um, Is that the trend or could you talk more about the trend in collagen sales that you're seeing and how we should look forward to the second half of the year? Thank you.

Yeah, I think so. You know, I just kind of, you know, I would sort of rephrase it a little bit from last year. You know, what we saw was a slight oversupply in the market, more so of gelatin. We did see some collagen. You know, I think what's important to understand is in order to make hydrolyzed collagen, you have to have let's call it gelatin extraction capacity that you're building it on top of. What we've experienced throughout this entire period is a consistent increase in demand for hydrolyzed collagen. What we saw last year was just a lot of our competitors putting capacity in the market on a short-term basis. There was a bit more supply of hydrolyzed collagen relative to demand than there had been prior to that. But now very quickly, we're starting to reverse that trend. And what's exciting about collagen going forward is the investment required to add new hydrolyzed collagen capacity is significant because you've got to have the extraction capacity behind it. That's a very large investment to make. So overall, what we see is a tightening of the gelatin supply and demand. Gelatin is not a fast-growing category, but it sort of grows at population rates. James Rattling Leafs, hydrolyzed collagen, on the other hand, is continuing to grow at very strong rates and so we're encouraged by that and and ourselves, you know we're well positioned with. James Rattling Leafs, With all of the hydrolyzed college and capacity that we have to continue to grow into that market and, as we form the joint venture you know with PV liner that's going to give us access to more capacity.

Thank you for your question. Our next question comes from the line of Puran Sharma with Steven. Your line is now open.

Thanks for the question. I just wanted to start off and hone in on guidance just a tad bit more. I think in prior calls, you'd given us a split of, you know, the core business versus DGD. Wanted to understand, you know, second half DGD doesn't sound like there's too much benefit in there. As you mentioned, you'll be offline for 3Q. You did mention that, you know, you'll be running in September. So I just wanted to understand, are you baking in more of a margin uplift in 4Q from the current environment? Just wanted to understand guidance with a bit finer detail.

Ron, this is Randy. Yeah, I think you framed it okay, but I think what I want to clarify for you is clearly the core ingredients business is accelerating all the way through the end of the year here. I mean, you know, if you look at the cash prices and you back into them, We were up about 3 cents a pound in fat in the mid 40s versus the low 40s in Q1. We're now well above 55 cents a pound on most FOB plants in North America now. That's a big number. Now, you've got to kind of balance that with the raw material price rise that happens during that process. Proteins have stabilized. James Rattling Leafs- demand for for global collagen is really consistent feels like the stockings done. James Rattling Leafs- That we've talked about in prior quarters, you know the big unknown in the in the guidance here is. James Rattling Leafs- You know, do we get a rim boost once that sre announcements out there, you know when does the market wake up, I think we use a lot of discussion around the table here with the team that. James Rattling Leafs, The RIN market the LCFS market because of the number of obligated parties does not react. James Rattling Leafs, Like a you know dynamic futures market that that's out there that reflects daily views and guidance and delivery and etc, etc, so you know the reality in our guidance here is we went forward was we said. We're confident in our core business and we love it. And we prefer to always talk about our core business. I think for the last five years, all I've done is talk about DGD. And we'll see if DGD becomes a meaningful contributor. The table is set with the RVO. There is no doubt about it. The question is timing here. You know, the guys always look at me and they know what line I'm about to bring you here. And that is, I've never made a bad trade, but I've lost a fortune in timing. And so right now, it's really a timing issue as to when this kicks in and all starts to react. I mean, you're seeing the bean oil complex, you're seeing crush margins react. They're now above the five-year average. I mean, this is a pretty darn good setup now as we enter fourth quarter. You know, Q3 said offline, no, we're down in August and we're ready to run full September 1. if margins are there. We're not going to run for fun and burn up catalyst until the time's ready.

Got it. Got it. Appreciate that color. I guess just real quickly on the follow-up, wanted to understand the SAF opportunity kind of in Europe. Obviously, you know, they have a really strong mandate, but wanted to understand it operationally. I think there's some nuances with the classifications that they allow. Could you help me understand that with a little bit finer detail? And I also just want to understand if there's any regulations in process that would make feedstock, you know, U.S. product a little bit easier to get into those markets.

I'll jump in quick, and Matt, you know, I think you're highlighting something that's important here, and that's all these different destination markets, they have different requirements as far as the feedstocks you can use in order to make the fuel, the certification body that's required in order to do that. These have presented challenges since the implementation of the policies that we're seeing. because it takes time to get those certifications in place and also to sort of get your supply chain sorted so you've got the right feedstocks coming in the door. I think one thing I would say, and this is a bit of an add-on to the last answer Randy gave, is when we look at Diamond Green Diesel and, you know, turning around Catalyst in Port Arthur, that really allows us to position that business well in the fourth quarter because because we can use that as an opportunity to put the right feedstocks in place that allow us to maximize destination markets that we're going to, earned duty drawbacks that we've got in reserve, all these kinds of things. And so as time goes on, all of that gets better and better because you've got those certifications in place, you've got the right supply chains coming in the door, but all that takes time to put in place.

Thank you for your questions. Our next question comes to the line of Betty Zhang with Scotiabank.

Your line is now open. Thank you. Hi, good morning. Thanks for taking my questions. My first question, you've kind of covered this, but I wanted to ask, is there a number you could or a range you could provide for the core business EBITDA for this year?

Yeah, I mean, you know, I think that that's that. Thank you, Betty, for asking that, because that's what everybody's been trying to ask. But you ask it straight up here. You know, it's very funny. I'm going to give you a 900 to a billion. So on the billion side, that's the fat prices flowing through, and that means the RINs don't react. If the RINs react, you know, we go way above that because the profitability of DGD will be much more than it's been today.

Perfect. Very clear. Thank you and thanks for the scenarios. Actually, I will just leave it there. All my questions have been covered. Thank you very much.

Thank you for your questions. Our final question comes from the line of Jason Gabelman with TD Securities. Your line is now open.

Hey. Hey, morning. Thanks for taking my questions. I wanted to go back to the RVO proposal, and I understand, you know, there'll be more clarity once the small refinery exemptions get announced. But, you know, there's probably some conservatism among investors just given they have been burnt in recent past on regulations. So I imagine they'd want to see the proposal finalized. And to that end, you know, there's a lot in that RVO proposal. In your views and conversations with the administration, are there things within the proposal that you think are sacred cows, more firm versus items that you think are more trial balloons that could not make it into the final rule?

Jason, this is Matt. Good morning. I would say quickly that... T. First of all, if there was the the public comment period is still ongoing and it's going to run through the first third the early days of August, and so that that is when there was a virtual in person. T. comment that went on in there, a few weeks ago, a lot of written comments are being submitted as we speak, so it's hard to say from that if anything comes out, you know I would say at the at the headline level. The administration remains very supportive of the RVO and the RVO process and is looking for something that is going to support the industries and the ag community. And so that's the headline. Now, the SREs is, I think I mentioned, you know, we're expecting that to come in the next few weeks and then the RVO to be finalized in October. So that's the timelines. Are there things in play there? I'm sure. uh which ones and to what extent that that remains to be open other than the fact that our view is that the the administration is is very supportive of a a solid uh rbo uh and and on the long-term basis yeah jason this is bob i just i would i think you know what when we when you read the tea leaves um

You know, it seems like the priorities, and we're encouraged by this, is that, you know, one is this policy needs to support U.S. farm prices. That's first and foremost. Second, it's got to minimize cost to the federal government. So those are some of the important changes. And then third is protecting, you know, U.S. industry, U.S. biofuel industry. You know, some of these things, the announced policies probably could change, but ultimately we believe they're going to try to achieve those three goals. and and and whatever that outcome is you know we we think it's going to be positive bob we've got the the two issues here sre and then the 2024 you want to comment about yeah i guess the other is is that normally 2024 rin compliance would be obligated as of march 31st of this year and uh until they formally uh uh revise the d3 rin uh numbers from 2024 That date is not fixed, you know, whether that's going to be October 1st or November 1st, it's unclear, but you know, that's the other, other piece to this is that compliance is required in order, in our view, in order for the real RIN S and D for 2024 to, to, to kind of show itself and then 2025 as well. And, you know, our view of the RIN S and D, when you look at the D6, D4, D5 altogether,

is uh is we're at a deficit for 25 and and certainly will be at 26 and so as long as compliance is enforced uh you know we believe we'll see higher ends and that'll result in a in a decent margin for renewable diesel got it thanks appreciate that and my follow-up is just on uh status of the monetization of 45z i think on the last call you were optimistic that you would have something in place by this time um just wondering how those conversations are going thanks

this is randy i'll take that so um we are very close to to where we thought we would be right now um you know these are somewhat new and uh it's kind of uncharted waters out there but i would just tell you to stay tuned there's nothing that's changed on our side that doesn't say that won't be accomplished here very shortly um you know in the land of lawyers there's too many involved

Thank you for your questions, Jason. That'll be all the questions in our Q&A session today. I would now like to turn the call back to Randy for final remarks.

Hey, thank you. Thank you, everybody. Great questions today. Leave you with a couple thoughts. Number one, we appreciate the interest in the company. We appreciate your patience. We have a positive outlook for the balance of the year, especially in the core ingredients. Some timing unknowns in Diamond Green Diesel products. But that asset, as you'll see over the next 10 days, as other people release, is still what I believe to be the best in class out there and poised to really deliver for us in 2026. So be safe. We look forward to talking to you again here, I believe, in October.

That concludes today's call. Thank you for your participation and enjoy the rest of your day.